PubMed Health⌕ Search

PubMed · 11237440

Vesicle Phases with Semipolar Additives.

Abstract

We examined the influence of semipolar additives on the phase behavior of mixed zwitterionic surfactant/consurfactant systems. It is shown that in these systems with increasing concentration esters like hexylacetate (HA) and ketones like hexylmethylketone (HMK) can behave both like consurfactants and like hydrocarbons. In solutions of 200 mM tetradecyldimethylamineoxide (TDMAO)/cosurfactant the additives cause first a phase transformation from the micellar L(1) phase to a lamellar L(alpha) phase. Upon further increasing concentration, the L(alpha) phase is transformed into a microemulsion. The L(alpha) phase consists of densely packed multilamellar vesicles. The vesicles are shown by electron microscopy. The multilamellar character of the vesicles is also reflected in the conductivity of the phase. It is up to 10 times lower than the conductivity of the L(1) phase. In some systems the vesicles are transformed on rest into a multidomain stacked L(alpha) phase. It is furthermore demonstrated that the two-phase L(1)/L(alpha) region in these systems is very narrow. In situations where enough HA is added to be close to the boundary of the L(1) phase, it is shown that very small amounts of cosurfactant can transform the L(1) phase into the L(alpha) phase. In extreme situations 1 mM cosurfactant is sufficient for transforming the L(1) phase with 200 mM TDMAO into the L(alpha) phase. In the investigated systems the L(alpha) phase is a highly viscoelastic fluid in which the storage modulus is 1 order of magnitude larger than the loss modulus. Besides the conventional way to prepare samples by adding all ingredients and stirring the solution intensively, all investigated systems were additionally prepared without applying any shear forces. In a surfactant/cosurfactant solution the additive was brought into the sample by diffusion. The phase behavior of both types of samples showed fundamental differences in some cases, which give insight into the influence of shear forces on these systems. Copyright 2001 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H. Hoffmann, K. Horbaschek, F. Witte. 2001-03-01. Vesicle Phases with Semipolar Additives.. https://doi.org/10.1006/jcis.2000.7238

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗